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Abstract 
This "Deep Insight" is a detailed subchapter of a general review article and summary on Internet databases for 
cytogeneticists: Internet databases and resources for cytogenetics and cytogenomics. 
Introduction 
Most gene fusions alter the expression and/or the 
function of normal genes, and they are generally 
strong driver mutations in neoplasia. They can 
provide important information for the classification 
of tumors (e.g. the well-known problem of "small 
round blue cell tumors") and may become the target 
for therapy (e.g. tyrosine kinase inhibitors). Since the 
discovery of the "Philadephia chromosome" 
(BCR/ABL1 fusion), hundreds and thousands of 
gene fusions have been highlighted. 
Several sets of hybrid genes (or "fusion genes") have 
been published during the last few years. 
The main resources in cytogenetics deal "every 
minute-every day" with all the structural and 
numerical chromosome rearrangements: 
translocations ("t"), inversions ("inv"), insertions 
("ins"), dicentrics ("dic", accompanied with "ace" 
when the dic occurs) (generating many hybrid 
genes/fusion proteins at the origin and/or in the 
process of cancer development), and also deletions 
("del"), duplications ("dup") (generating hybrid 
genes at the breakpoints, and/or gene copy number 
changes), isochromosomes ("i"), double minus 
("dm") and homogeneously staining regions 
("HSR"), monosomies and trisomies, with massive 
gene copy number changes, marker chromosomes, 
with high levels of any possible abnormality, and 
rings ("r"), so instable that their significance, in term 
of carcinogenesis, at the cell level, remains 
anecdotic/unpredictable/unknown (see 
http://atlasgeneticsoncology.org/Educ/PolyMecaEn
g.html).
Various types of databases have been developed. 
Majority of this data is integrated in the COSMIC 
database (as studies presented in 
http://atlasgeneticsoncology.org/cosmicstudies.html
) or in the Mitelman database resulting in redundant 
information in various databases. 
The Atlas of Genetics and Cytogenetics in Oncology 
and Haematology (http://atlasgeneticsoncology.org) 
provides peer reviewed articles/cards on 
chromosome abnormalities, clinical entities and 
genes. 
Primer sequences for the verification for hybrid 
genes can be provided in the literature (Lovf M et al., 
2011; Skotheim RI et al., 2009; Urakami K et al., 
2016).  
Hybrid genes can be present in tumors but as well in 
normal tissues (Babiceanu M et al., 2016). 
General resources in Genetics and/or Oncology De Braekeleer E, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2016; 20(6) 360 
 
 
Figure 1: Mitelman database: "Cases Quick Searcher", "Molecular Biology Associations Searcher", and "Clinical Associations 
Searcher" (http://cgap.nci.nih.gov/Chromosomes/AllAboutMitelman) 
 
 
The International System for Human Cytogenetic 
Nomenclature (ISCN) is the nomenclature used to 
describe normal and abnormal karyotypes. 
Languages with specific grammars have been 
invented in logic and in mathematics with specific 
grammars (see 
https://en.wikipedia.org/wiki/Portal:Logic). The 
ISCN follows this model. It uses operands and, to act 
on them, unary and binary operators (e.g. "r" (ring) 
is an unary operator because it acts on one operand 
(one chromosome), and "t" (translocation) is a binary 
operator, because it acts on two operands, (the 2 
chromosomes involved in the translocation). ISCN 
originates at the Denver conference, in 1960 
(Proposed standard, 1960). Revisions and updates of 
the ISCN made the interpretation more difficult 
(ISCN 2013). A new version is being released by the 
end of 2016 (McGowan-Jordan J et al. (2016) but 
will not be freely available on the web. 
I- Chromosome 
rearrangements/Hybrid genes 
I-1 Mitelman Database  
The Catalog of Chromosome Aberrations in Cancer, 
containing 3,844 cases, was first published in 1983. 
Successive printings were published by Karger, 
Allen R Liss, and Wiley-Liss (Sixth Edition, 1998). 
In 2000, the support of the National Cancer Institute 
(NCI) pushed the Catalog to be an open online 
database (Figure 1). The last update in Februrary 
2016, included a total number of cases amounting to 
66,479, implicating 10,277 gene fusions (Heim S 
and Mitelman F, 2015). The information is manually 
collected from literature and subsequently organized 
into distinct sub-databases: The "Cases Quick 
Searcher" and the "Cases Full Searcher" contain the 
information related to chromosomal aberrations in 
individual cases, with the specific tumor 
characteristics.  
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The "Molecular Biology Associations Searcher" 
compile events according to the gene 
rearrangements, with a mention to tumor histologies 
(Figure 2). It is accessed by a Gene List" (from A2M, 
A2M/ALK, A2M/ARFGEF2, to ZZZ3/NCK1). The 
"Clinical Associations Searcher" has established its 
database on tumor type, related to chromosomal 
aberrations and/or gene rearrangements. The starting 
point is the "Topography List" presenting the 
location of the tumor (from Adrenal, Anus, Bladder, 
Blood vessel, Bone to Vagina), paired with a 
"Morphology List", according to histology subtypes 
of the tumor (from Acinic cell carcinoma, Acute 
basophilic leukemia, Acute eosinophilic leukemia, 
to Wilms tumour. It is possible to find other sub-
databases: "Recurrent Chromosome Aberrations 
Searcher", providing a  
way to search recurrent chromosome abnormalities, 
and the "Reference Searcher", which enquires the 
bibliographic references.  
Each sub-database specifies pertinent references 
with PMID numbers hyperlinked to PubMed. 
This free access database shows raw data; it is 
(almost) finished, showing approximately 99.9% of 
the different published chromosomal 
rearrangements, and very reliable (each case is 
manually collected by prominent experts: Felix 
Mitelman, Bertil Johansson, and Fredrik Mertens). 
The Mitelman catalog and database is still an 
indispensable assistant to every cancer 
cytogeneticist.  
Taking in consideration all the progress made in 
cancer cytogenetics, it would have been much slower 
without the Mitelman database. 
 
 
 
Figure 2: PAX5/JAK2 in the Mitelman database (http://cgap.nci.nih.gov/Chromosomes/MSearchForm, click on: "Expand Gene 
List", quote: PAX5/JAK2) 
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I-2 Atlas of Genetics and 
Cytogenetics in Oncology and 
Haematology 
The Atlas of Genetics and Cytogenetics in Oncology 
and Haematology (Dorkeld et al., 1999; Huret al al., 
2013) (http://atlasgeneticsoncology.org) is a peer 
reviewed all in one freely available online journal 
(ISSN: 1768-3262), encyclopaedia and database. It 
is an integrated structure and includes the following 
topics: genes, cytogenetics and clinical entities in 
cancer, and cancer-prone diseases. The Atlas 
combines various types of information: genes, gene 
rearrangements, cytogenetics, protein domains, 
function, cell biology, pathways. It also encloses: 
clinical genetics, cancer prone hereditary diseases 
and diseases, focused on cancers and other medical 
conditions. The collection of all these different data 
helps to unify cancer genetics, while data found 
elsewhere is dispersed between several sites. The 
Atlas is the only cancer genetics database quoting 
prognosis. The iconography in the Atlas (32,554 
images) is diverse (medical imaging, pathology, 
chromosomes, 3-D structure of proteins, genetic 
maps...). 
The objectives of the project is to transfer scientific 
innovation towards research itself, and more 
precisely towards patient care (translational health 
research), medical treatment assistance in rare forms 
of cancer, making the fight against cancer more 
efficient, decrease the costs in fundamental, applied 
research and medical, toward a personalised cancer 
medicine. It is also an appliance for researchers in 
genomics. 
Content: The Atlas contains 45,500 pages (30,519 
documents) written from 3,216 authors from roughly 
50 countries (in decreasing order: France, USA, 
Italy, United Kingdom, Germany, Japan, Spain, 
Canada, China, The Netherlands...).  
The Atlas is mainly constituted of structured review 
articles or "cards" (original monographs written by 
invited authors), but also contains traditional 
overviews, a portal directed to websites and 
databases dedicated to cancer and/or genetics, case 
reports in haematology, and various languages 
teaching items.  
The Atlas constitutes a fountain of knowledge 
regarding the biology of normal and cancerous cells. 
There are 1,460 genes annotated cards (e.g. TP53 
http://atlasgeneticsoncology.org/Genes/P53ID88.ht
ml), and 27,800 non-annotated cards on genes, 600 
leukemias (e.g.Classification of myelodysplastic 
syndromes 
http://atlasgeneticsoncology.org/Anomalies/Classif
MDSID1058.html ; see also Figure 3), 210 solid 
tumors (e.g. Head and Neck Paraganglioma, an 
overview 
http://atlasgeneticsoncology.org/Tumors/HeadNeck
ParagangliomaID6202.html ), 115 cancer prone 
diseases (e.g. Oculocutaneous Albinism 
http://atlasgeneticsoncology.org/Kprones/Oculocuta
neousAlbinismID10022.html), and 110 Deep insight 
(e.g. The nuclear pore complex: structure and 
function 
http://atlasgeneticsoncology.org/Deep/NuclearPore
FunctionID20139.html). The Atlas items are usually 
looked up by chromosome or using the search box 
for genes or chromosomal abnormalities, in 
dedicated pages for solid tumors or for cancer-prone 
diseases. However, a "Search by Chromosome band" 
has recently been developed: it is a synthesis of all 
hybrid gene resources for each chromosome band, 
representing 435 pages presenting the chromosomal 
abnormalities, genes implicated, associated with 
collected data from databases, the literature and links 
to the original web sites. (e.g. 
http://atlasgeneticsoncology.org/Bands/1p36.html) 
 
 
Figure 3 t(9;9)(p13;q24) PAX5/JAK2 in the Atlas (http://atlasgeneticsoncology.org/Anomalies/t0909p13p24ID1559.html) 
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Annotations/Meta-analyses: The Atlas is the only 
database that gives annotated data with meta-
analyses (e.g. survival curves in the t(3;21)(q26;q22)  
RUNX1/MECOM 
(http://atlasgeneticsoncology.org/Anomalies/t0321I
D1009.html) or in the t(1;11)(p32;q23) 
KMT2A/EPS15 
(http://atlasgeneticsoncology.org/Anomalies/t0111p
32q23ID1046.html), which are calculated from the 
available cases in the literature. Also, the uniquely 
detailed description of the gene SQSTM1 domains 
(http://atlasgeneticsoncology.org/Genes/GCSQST
M1.html) is the result of a careful annotation of 
collected data from various research papers. Since 
2000 the Atlas has started to use radiating circle as a 
way to illustrate partner genes in a translocation (see 
http://atlasgeneticsoncology.org/Partners.htm), and 
since then the use has largely expanded. 
Diagnosis and treatment: The Atlas may contribute 
to the cytogenetic diagnosis and may guide treatment 
decision making, particularly regarding rare diseases 
(numerous, rare diseases are frequently 
encountered). From the section "Genes", one can 
obtained 600 genes implicated in , 732 in breast 
cancer, and 480 genes in prostate cancer (e.g. see 
paragraph "Other genes implicated" at: 
http://atlasgeneticsoncology.org/Tumors/breastID5
018.html). The improving development of technics 
in genetics, it now appears that many subtypes of 
solid tumors may exist (there are potentially 
hundreds of breast cancer subtypes defined by 
distinct genetic profile yet to be uncovered), 
following the leukemia model. 
Recently, new information on lung adenocarcinoma 
might give the possibility to consider personalized 
medicine (see 
http://atlasgeneticsoncology.org/Tumors/TranslocL
ungAdenocarcID6751.html ). Together with cell 
biology developments, proves that the encyclopaedic 
content of the Atlas and other similar data sources 
are probably a basis for developing personalized 
medicine for cancer. 
ICD-O3 nomenclature: Nosology and phylum of 
solid tumors and hematological cancers can be found 
in the Atlas at 
http://atlasgeneticsoncology.org/Tumors/SolidNoso
logy.html and 
http://atlasgeneticsoncology.org/Anomalies/ICD-
OHematology.html. 
Cell biology and physio-pathology: Information on 
cell biology and physio-pathology, can be found in 
specific pages of the Atlas (e.g.: Angiogenesis: 
http://atlasgeneticsoncology.org/Categories/Angiog
enesis.html). 
Links: More than 17,000 internal hyperlinks in the 
Atlas can be found. Gene cards are broadened by 
external links to up to date databases filing 
complementary aspects. 
Educational tools: The Atlas has also worked in 
developing educational tools in genetics in English, 
Spanish, and French (e.g. 
http://atlasgeneticsoncology.org/GeneticFr.html). 
Altogether with the information described above, 
this constitutes a step in the continuing medical 
education. 
Electronic journal: An Open access electronic 
journal/pdf version of the Atlas has been developed 
by Institute for Scientific and Technical Information 
(INIST) of the French National Centre for Scientific 
Research (CNRS). Available are the archives of a 
quarterly journal since 1997, which became a 
bimonthly journal in 2008 and a monthly journal in 
2009, comprising 2,500 articles in more than 120 
volumes, which constitutes a 10,000 pages 
collection, available at: 
http://irevues.inist.fr/atlasgeneticsoncology. On the 
other hand, the Atlas is an encyclopedia with 45,000 
pages of reference work, unfortunately stays 
incomplete and partially dated. As a product of 
collaborative work, the accuracy and the renewal of 
the Atlas is dependent on colleague participation. 
I-3 COSMIC 
(http://cancer.sanger.ac.uk/cosmic)  
COSMIC is a catalog of somatic mutations in cancer, 
developed by the Sanger Institute with the support of 
the Wellcome Trust. It approximately includes all 
abnormalities, from single nucleotide variations to 
chromosome rearrangements / hybrid genes. 
COSMIC includes and displays somatic mutation 
information, related details and contains information 
related to human cancers. For hybrid genes, 
COSMIC describes in v76 (Feb 2016) 17,245 
fusions, with 283 fusion genes which are cured, and 
1,271 different pairs when taking inferred 
breakpoints into account (Figure 4). These fusions 
are part of a global database that is mainly 
regrouping somatic mutations in cancer. All the 
fusions are identified with a code (ex: COSF699) and 
defined on the genome with the standardization of 
HGVS (http://www.hgvs.org/mutnomen/recs-
DNA.html) (ex: 
PLXND1{ENST00000324093}:r.13016TMCC1{E
NST00000393238}:r.9185992) (Forbes SA et al., 
2015). 
(http://cancer.sanger.ac.uk/cosmic/fusion/summary?
id=1071) A synthesis of all these resources is 
integrated in chromosomal band pages of the Atlas 
(http://atlasgeneticsoncology.org/Bands/1p36.html#
GENES) with links to the original websites. 
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Figure 4: PAX5/JAK2 gene fusion at COSMIC 
 
I-4 ChimerDB 2.0 
(http://biome.ewha.ac.kr:8080/FusionGene/) 
ChimerDB 2.0 is a database for hybrid genes 
updated in 2010, with PubMed references and 
various information about the structure of chimeric 
genes. (Kim N et al., 2006a ; Kim P et al., 2006b). 
I-5 TICdb 
(http://www.unav.es/genetica/TICdb/) 
TICdb (v 3.3 August 2013) is a database of 
Translocation breakpoints In Cancer (Novo FJ et al., 
2007). This update contains 1,313 sequences of 
hybrid genes found in human tumors, involving 420 
different genes (Figure 5). For every fusion, TICdb 
will return the HGNC names of both partner genes 
and the original reference (either a GenBank or a 
Pubmed ID), as well as the fusion sequence at the 
nucleotide level. A complete list of genes and the 
fusion sequences can be obtained at 
http://www.unav.es/genetica/allseqsTICdb.txt. 
I-6 ChiTARS 
(http://chitars.bioinfo.cnio.es/) 
ChiTARS is a database of chimeric transcripts 
obtained by the analysis of EST or RNA sequencing 
with part of experimental validation. This database 
including 20,750 chimeric human transcripts, has 
been developed within the ENCODE project 
(Frenkel-Morgenstern M et al., 2013 ; Frenkel-
Morgenstern M et al., 2015). 
I-7 TCGA Fusion gene Data Portal 
(http://54.84.12.177/PanCanFusV2/) 
TCGA Fusion gene Data Portal presents the analysis 
from 20 tumor types of the TCGA program, as of 
December 2014, with 10,431 fusions in 2,961 tumors 
with fusions (a mean of 3.5 fusions per sample) 
(Yoshihara K et al., 2015). This is the result of a 
specific pipleline for RNA Seq data analysis 
(PRADA) developed at the MDAndersson Cancer 
Center. 
I-8 Fusion cancer 
(http://donglab.ecnu.edu.cn/databases/FusionCance
r/) (Wang Y, 2015). 
This database of hybrid genes in human cancers 
originated from the analysis of RNA-seq data in the 
Sequence Read Archive (SRA) on NCBI in 15 
cancer types and contains 11,839 fusions, with 
structured information on cancer types, breakpoint 
accession numbers of SRA and chimeric sequences. 
I-9 OMIM 
(http://www.omim.org/ see General resources in 
Genetics and/or Oncology) 
The "Online Mendelian Inheritance in Man" 
(OMIM) catalog encloses 1,523 entries with "fusion 
gene" (Amberger JS et al., 2015). 
I-10 Other resources 
Books: "Cancer Cytogenetics: Chromosomal and 
Molecular Genetic Abberations of Tumor Cells", by 
Sverre Heim and Felix Mitelman, is published by 
Wiley-Blackwell Ref. This major textbook is the 
fourth edition (2015) and contains 648 pages. Some 
useful iconography of chromosome rearrangements 
from the UWCS laboratory, University of 
Wisconsin, can be found at 
http://www.slh.wisc.edu/clinical/cytogenetics/cance
r/. An analysis of hybrid genes in 675 tumor cell lines 
has been performed by GenenTech (Klijn C et al., 
2015). Of the 2,200 gene fusions catalogued, 1,435 
consist of genes not previously found in fusions. A 
synthesis of cell lines analyses can be found in the 
Atlas at 
http://atlasgeneticsoncology.org/celllines.html. 
Finally, the Mitelman and the Atlas being 
complementary, the recommendation is that both of 
these indispensable databases should be used. 
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Figure 5: PAX5 hybrid genes at TicDB (http://www.unav.es/genetica/TICdb/results.php?hgnc=PAX5&x=23&y=8) 
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II- Data for SKY and FISH 
Fluorescence in-situ hybridization (FISH) technique 
facilitates the identification of chromosomal 
structures to be identified using specific probes. This 
significantly improves the localisation of 
breakpoints on chromosomes by a direct view of 
hybridization of probes using one or several colors 
associated with the probes. The big advantage of the 
FISH technique is that it can also be used on non-
dividing cells (interphase nuclei). BAC clones are 
used for mapping studies as they contain large inserts 
of human DNA and can be fluorescently labeled to 
determine the localization of genes and identify 
regions implicated in cancer chromosomal 
aberrations. The Cancer Chromosome Aberration 
Project (CCAP) has created a set of BAC clones 
mapped cytogenetically by FISH and physically by 
STSs to the human genome. The BAC data is 
integrated into various CGAP and NCBI databases 
to provide related clinical, histopathologic, genetic, 
and genomic information 
(http://cgap.nci.nih.gov/Chromosomes/CCAPBAC
Clones) and more precisely for each chromosome 
(e.g. 
http://cgap.nci.nih.gov/Chromosomes/BACCloneM
ap?CHR=6). 
The Human BAC Array 
(http://mkweb.bcgsc.ca/bacarray/ is built using 
32,855 clones from RPCI-11, RPCI-13, Caltech-D 
BAC libraries. The set achieves an average depth of 
coverage of 1.8X, average effective resolution of 76 
kb. Genome-adjacent clones in the set overlap by an 
average of 73 kb. The set provides coverage of 98% 
of the human hg17 (May 2004) genome assembly 
and 98% of the human May 2005 BAC fingerprint 
map. The clone set is publically available from 
BACPAC Resources. An easy way to select them is 
by the Cytogenetic Resource of FISH-mapped, 
Sequence-tagged Clones at NCBI 
(http://www.ncbi.nlm.nih.gov/genome/cyto/cytobac
.cgi?CHR=6&VERBOSE=ctg). 
All BAC can be located on the UCSC genome 
browser (http://genome.ucsc.edu) when BAC end 
pairs track is selected. On the other hand, BAC from 
the fishClones file can be visualized on the 
chromosomal bands on the Atlas 
(http://atlasgeneticsoncology.org/Bands/) that has a 
link to their GenBank sequences. 
More recently, several commercial companies have 
developed more specific catalogs of FISH clones as 
oligonucleotides probes (see also the chromosome 
pages of the Atlas for links). With differently 
labelled DNA probes (in general as a mixture), 
combined green/red signals colocalize in yellow in 
normal cells. In a chromosome translocation the co-
localized signal will split, resulting in separate green 
and red signals, the unaffected chromosome 
remaining with a yellow signal. 
Concerning the SKY techniques, there are some 
resources such as a SKY/M-FISH &CGH database 
at the NCBI (which provides a public platform for 
investigators to share and compare their molecular 
cytogenetic data http://www.ncbi.nlm.nih.gov/sky/), 
with an ICD-O3 nomenclature (International 
Classification of Diseases - Oncology). Elsewhere, 
there are some others resources as SKY Karyotypes 
and FISH analysis of Epithelial Cancer Cell Lines at 
Cambridge (http://www.pawefish.path.cam.ac.uk/). 
III- Comparative genomic 
hybridization (CGH) resources 
In 1992, Dan Pinckel (Kallioniemi A et al., 1992) 
developed the comparative genomic hybridization 
(CGH) independently of the morphological analysis 
of chromosomes. In the first step of development, 
CGH was used on metaphases. But at the end of 1990 
Solinas-Toldo (Solinas-Toldo S et al., 1997) and 
Pinkel et al. (Pinkel D et al., 1998) proposed a new 
technique of DNA hybridization on array (first 
spotted with cDNA, but rapidly, after 2002, with 
synthetized (50-80 mers) oligonucleotides. The 
genomic resolution was increased below 50-100 
nucleotides, as the density of probes is, in parallel, 
increased from 20K to up 2M. Because it is a method 
of a ratio of copy numbers (often defined as log2 of 
the ratio) this technique only detects disequilibrium 
between a disease sample and a normal sample, and 
it has been applied to several aspects of genetic 
imbalances. Numerous arrays have been designed 
(from pan-genomic to specific of some abnormalities 
(custom design)). For example the GEO server 
(Gene Expression Omnibus) has 432 CGH platforms 
(with 233 as human) and 71 SNP (with 46 for 
human). 
The processing of CGH data is not obvious (with 
normalization of the raw data, centralization, 
segmentation in pieces of chromosomes with 
homogeneous copy number limited by breakpoints, 
and finally annotation of implicated genes). An 
optimal profile of copy number associated with 
accurate breakpoints requires normalization (with 
correction of GC content) and centralization 
(especially when the profile has a great part of 
abnormalities). This optimization also depends on 
the nature of the sample (such as clonality or the 
percentage of tumor cell). It is important to note the 
impact in clinical routine to define, for example, 
actionable genes (Commo F et al., 2015). Another 
extension of this approach are the SNP arrays that 
combine probes designed for copy-number 
measurement and probes specific of a known 
nucleotide variant ("single nucleotide 
polymorphism"). The great advantage is the 
possibility to measure the ploidy (which cannot be 
measured by CGH alone, as the measure is a relative 
value, depending on the percentage of tumor cells). 
Moreover, the segmentation of copy number can be 
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correlated with the segmentation of LOH (loss of 
heterozygosity), which gives a better interpretation 
of the origin of abnormalities. Several sites are 
repositories for these CGH/SNP profiles: 
III-1 GEO 
(http://www.ncbi.nlm.nih.gov/geo/) 
GEO (Gene Expression Omnibus) is a public 
functional genomics data repository supporting 
MIAME-compliant data submissions. Array and 
sequence-based data are accepted. Tools are 
provided to help users query and download 
experiments and curated gene expression profiles. 
This database includes curated gene expression 
DataSets, as well as original series and platform 
records in the GEO repository. Mainly used for gene 
expression, GEO has a limited part dedicated to 
CGH datasets (1,358 experiments for human 
neoplasms). It is not easy to synthetize the variation 
of copy number results directly on the site. The best 
way is to export (as GSExxxRAW.tar) and reanalyze 
the data with a specific software (as Bioconductor 
packages or commercial companie's tools (Clough E 
and Barrett T, 2016). 
III-2 Array Express 
(http://www.ebi.ac.uk/arrayexpress/) 
Array Express is a similar archive of functional 
genomics data, stored data from high-throughput 
functional genomics experiments, and provides these 
data for the reuse for the research community 
(Petryszak R et al., 2016). There are several other 
sites that present reanalyzed data (public or local) 
with various analytic approaches and provide 
facilities for exploring abnormalities in different 
types of tumors. 
III-3 Tumorscape 
(http://www.broadinstitute.org/tcga/home) 
This portal (Broad Institute), created in 2010, is 
designed to facilitate the use and understanding of 
high resolution copy number data amassed from 
multiple cancer types. The 3,131 datasets are partly 
originating from GEO and reanalyzed with the 
GISTIC algorithm to identify regions that have been 
altered above the background rate and therefore may 
be subject to positive selection. For each of these 
regions, one or more "peak regions", most likely to 
contain the target genes, are identified (Beroukhim 
R et al., 2010). The following functionalities are 
supported: - Gene-level Analysis: One can query the 
level and significance of copy number alterations 
affecting any gene listed in Refseq (or miRNAs). 
Click "Analyses", then "by Gene". - Analysis by 
cancer type: One can query the most significant 
regions of amplification and deletion in individual 
cancer types. Click "Analyses", then "by Cancer 
Type". In Analysis by Gene, these data represent a 
GISTIC analysis performed on this cancer type. 
Across a large number of cancers, copy number 
alterations (amplifications or deletions) can be found 
almost anywhere in the genome. GISTIC identifies 
regions that are altered above the background rate 
and therefore may be subject to positive selection. 
For each of these regions, one or or more "peak 
regions", most likely to contain the target genes, are 
identified. The evidence that a gene is targeted by 
these copy number alterations includes: i) Presence 
in a peak region: these peak regions are the regions 
deemed most likely by GISTIC to contain the gene 
or genes being targeted by significant 
amplifications/deletions; ii) a significance (Q-
value): this represents the likelihood that the gene 
only suffers amplifications/deletions at the 
background rate across the entire genome. The data 
can be visualized on the IGV (Integrated Genome 
Viewer). 
III-4 MetaCGH 
(http://compbio.med.harvard.edu/metacgh/) 
This website is designed to provide access to array 
CGH (comparative genomic hybridization) based on 
copy number profiles of 8,227 human cancer 
genomes (Figure 6). See the description of the 
database for more information about its composition 
(Kim TM et al., 2013). An interactive web-based 
browser facilitates the exploration of the result set: - 
Search for specific genes of interest. Support 
alternative gene nomenclatures. - Browse cytobands 
by frequency of alteration. - Visualize alteration 
frequency over the full set of tumor types for a gene 
of interest. 
III-5 CaSNP 
(http://cistrome.org/CaSNP/) 
CaSNP is a comprehensive collection of copy 
number alterations (CNA) from SNP arrays. It 
collects 11,485 Affymetrix SNP arrays of 34 
different cancer types in 105 studies to profile the 
genome-wide CNA and SNP in each. This includes 
all the cancer SNP profiles using Affymetrix SNP 
arrays (10K to 6.0) with raw data from GEO, with 
additional arrays from the TCGA consortium and a 
few individual publications. All CNA data stored in 
CaSNP is generated from raw data analyzed by 
dCHIP-SNP software. Data can be visualized as 
table or heatmap. (Cao Q et al., 2011).  
III-6 Cell line Project 
(http://cancer.sanger.ac.uk/cell_lines)  
For decades, human immortal cancer cell lines have 
constituted an accessible, easily usable set of 
biological models. In order to improve their utility 
the Cancer Genome Project has embarked on a 
systematic characterization of the genetics and 
genomics of large numbers of cancer cell lines. Prior 
knowledge of their genetic abnormalities may allow 
more informed choice of cancer cell lines in 
biological experiments and drug testing and more 
informed interpretation of results. Among other 
information (exome sequencing) the COSMIC Cell 
Lines Project includes genome wide copy number 
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analysis and genotyping information obtained by 
using the Affymetrix SNP6 array and analyzed by 
using the PICNIC algorithm.  
A complete list of cell lines can be found on 
http://cancer.sanger.ac.uk/cell_lines/cbrowse/all. 
III-7 Cancer Cell Line 
Encyclopedia 
(http://www.broadinstitute.org/ccle/home) 
For several years, the Broad Institute has developed 
resources for cell lines data, especially copy number 
analysis with Affymetrix SNP6.0 arrays. These last 
two resources are complementary. Several other 
sites presenting global resources from TCGA or 
ICGC programs give access for each disease by copy 
number analysis (e.g. Broad GDAC FireBrowse, 
cBioPortal (see below), OASIS portal ....) 
III-8 ArrayMap 
(http://www.arraymap.org)  
ArrayMap is a curated reference database and 
bioinformatics resource targeting copy number  
profiles that provides an entry point for meta-
analysis and systems level data integration of high-
resolution oncogenomic CNA data. The current  
data reflects 65,042 genomic copy number arrays, in 
986 experimental series and on 333 array platforms 
(Cai H et al., 2015). A main interest of these 
resources (originating in great part from GEO 
datasets) is the fine classification with the ICD-O3 
nomenclature.  
This resource is an elaborate and complete site for 
querying large amount of CGH data of cancer.  
For the majority of the samples, probe level 
visualization and customized data representation 
facilitate gene level and genome wide data review. 
Results from multi-case selections can be connected 
to downstream data analysis and visualization tools 
(as linear, circularized or karyotype like 
presentations). Numerous tools permit visualization 
of part of profiles (selection of chromosomes or 
genes) and export of data in tabulated files. An API 
(with relatively easy syntaxes) facilitates an 
automation of analyses. Moreover a majority of 
cards (leukemia or solid tumors) in the Atlas are 
linked, via ICD-O3 codes, to ArrayMap (Figure 7). 
 
Figure 6: PAX3 gain and loss in tumors at MetaCGH (http://compbio.med.harvard.edu/metacghBrowser/). 
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Figures 7: ArrayMap (http://www.arraymap.org/) Selection of 26 samples of T lymphoblastic leukaemia/lymphoma (ICD-O 
9837/3) to obtain a "heatmap" of gain and loss for all the samples showing the variability of CGH profiles. 
 
IV- Mutation databases 
The difference between single nucleotide (SNP) as 
the variability within a population and mutations 
acquired in a neoplastic process is extremely crucial. 
The determination of variants was previously 
obtained by SNP arrays, but is nowadays performed 
by massive parallel sequencing. As a result, a huge 
quantity of polymorphisms and mutations in tumors, 
are compared to controls. The landscape of the 
majority of recurrent mutations is now known and 
can be used for diagnosis.  
Even in haematological malignancies, where the 
chromosome rearrangements have shown to bear a 
major role, nonetheless, it appears now that some 
mutations at the nucleotide level can still be very 
important in determining treatments in relation to 
patient outcome (e.g. ASXL1, ATM, BCL6, BRAF, 
KRAS and NRAS, CBL, CCND3, CDKN2A and 
CDKN2C, CEBPA, CRLF2, ETV6, FLT3, GATA2, 
ID3, IDH1, IDH2, IKZF1, JAK1, KIT, MYD88, 
NOTCH1, NPM1, RUNX1, TP53). 
IV-1 COSMIC 
 (http://cancer.sanger.ac.uk/cosmic)  
COSMIC is designed to store and display somatic 
mutation information and related details and 
contains information relating to human cancers. In 
the v76 (Feb 2016), there are 3,942,175 mutations on 
1,192,776 samples collected in 22,844 papers. The 
interface has been fully redesigned and offers 
multiple ways to view mutations, fusions, copy 
numbers, etc. (Forbes SA et al., 2015).  
IV-2 CENSUS 
(http://cancer.sanger.ac.uk/census/) 
The Cancer Gene Census is an ongoing effort to 
include cancer genes for which mutations have been 
causally implicated in cancer. The original census 
and analysis was published in Nature Reviews 
Cancer and supplemental analysis information 
related to the paper is also available. The census is 
regularly updated. In particular, Felix Mitelman and 
his colleagues have been continuing to provide 
information on more genes involved in uncommon 
translocations in leukaemias and lymphomas. 
Currently, there is more than 1% of all human genes 
that have been mutated in cancer. Out of these, 
roughtly 90% cancer mutations are somatic, 20% 
bear germline mutations that predispose to cancer 
and 10% show both somatic and germline mutations 
(Futreal PA et al., 2004).  
IV-3 HGMD 
(http://www.hgmd.cf.ac.uk/ac/index.php) 
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The recognition that certain DNA sequences are 
hypermutable has yielded clues to the endogenous 
mutational mechanisms involved and has provided 
insights into the intricacies of the processes of DNA 
replication and repair (Cooper and Krawczak 1993). 
In practical terms, a fuller understanding of the 
mutational process may prove important in 
molecular diagnostic medicine by contributing to 
improvements in the design and efficacy of mutation 
search procedures and strategies for different genetic 
disorders. The Human Gene Mutation Database 
(HGMD) collects known (published) gene lesions 
responsible for human inherited disease. This 
database, whilst originally established for the study 
of mutational mechanisms in human genes (Cooper 
DN and Krawczak M, 1996) has now acquired a 
much broader utility in that it embodies an up-to-date 
and comprehensive reference source to the spectrum 
of inherited human genes. Thus, HGMD provides 
information of practical diagnostic importance to i) 
researchers and diagnosticians in human molecular 
genetics, ii) physicians interested in a particular 
inherited condition in a given patient or family, and 
iii) genetic counselors. Note: HGMD has two types 
of access: a free public one with limited data and a 
professional one requiring a license.  
IV-4 LOVD 
(http://www.lovd.nl/3.0/home) 
LOVD stands for Leiden Open (source) Variation 
Database. The LOVD's purpose is to provide a 
flexible tool for gene-centered collection and display 
of DNA variations. LOVD 3.0 extends this idea to 
also provide patient-centered data storage and NGS 
data storage, even for variants outside of genes. 
LOVD consist of both a database soltware and the 
content from Locus Specific Mutations databases 
(LSSB) (http://grenada.lumc.nl/LSDBlist/lsdbs) 
which are curated by laboratories. A general access 
gives links to each gene (92,241 entries in all) 
(Fokkema IF et al., 2011).  
IV-5 TCGA cBIoPortal 
(http://www.cbioportal.org/) 
The cBioPortal for Cancer Genomics provides 
visualization, analysis and access of large-scale 
cancer genomics data sets (126 in April 2016). For 
each dataset the portal presents several diagrams for 
mutations, copy number variations, survival analysis 
so on (Figure 8). It also provides help in analysing a 
list of predefined genes (Deng M et al., 2016). 
IV-6 ICGC Data Portal 
(https://dcc.icgc.org/) 
The ICGC Data Portal provides tools for visualizing, 
querying and downloading the data released 
quarterly by the consortium's member projects. The 
Pancancer Analysis of Whole Genomes (PCAWG) 
study is an international collaboration to identify 
common patterns of mutations in more than 2,800 
cancer whole genomes from the International Cancer 
Genome Consortium. It contains descriptions of 
36,985,985 mutations in 57,773 genes and 17,867 
donors within 66 projects in 21 primary sites (Zhang 
J et al., 2011).  
IV-7 OASIS Portal 
(see above) 
presents data from 30 datasets (from Acute Myeloid 
Leukemia to Uterine Corpus Endometrial 
Carcinosarcoma) with 6,817 mutations, 11,222 
CNVs and expression (8,178 RNA Seq and 4,889 
microarrays).  
IV-8 IntOGen 
(http://www.intogen.org)  
IntOGen collects and analyses somatic mutations in 
thousands of tumor genomes to identify cancer 
driver genes (Figure 9). At the end of 2014, IntOGen 
defines a list of 459 driver genes in 28 cancer types 
(Gundem G et al., 2010). 
IV-9 BioMuta v2 
(https://hive.biochemistry.gwu.edu/tools/biomuta/) 
BioMuta v2.0 is a curated single-nucleotide variation 
(SNV) and disease association database where the 
variations are mapped to the genome/protein/gene. 
Oriented toward cancer, the database has 5,233,790 
SNV for 41 cancer types and gives position of 
mutation and frequency in each cancer type (Wu TJ 
et al., 2014).  
IV-10 DoCM 
(http://docm.genome.wustl.edu/) 
The Database of Curated Mutations (DoCM) is a 
curated database of known, disease-causing 
mutations that provides easily explorable variant lists 
with direct links to source citations for easy 
verification. Curation of the literature to produce a 
high quality set of pathogenic somatic mutations is 
not straitforward.  
This requires sifting through the ever growing body 
of cancer research literature (6% annual growth rate 
in the last 10 years), which for year 2015 means over 
156,399 articles related to cancer as indexed by 
PubMed.  
This volume of literature makes it difficult to identify 
bona fide somatic mutations with characterized 
functional or clinical significance in cancer. Once 
identified, these mutations require significant 
curation efforts to format and standardize the 
mutations in a consistent way that enables databasing. 
For example, publications often only specify the 
amino acid change and gene name to describe the 
mutation. DoCM addresses these challenges by 
acting as an accessible, open-source, and openly 
licensed somatic mutation repository that also 
enables community contributions.  
General resources in Genetics and/or Oncology De Braekeleer E, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2016; 20(6) 371 
 
 
Figure 8: PAX5 alterations in cancer at cBioPortal (http://www.cbioportal.org/, Select Cancer Study, tick "all"; Enter Gene Set: 
"write; "PAX5") 
 
 
Figure 9: PAX5 mutation frequency at intOGen (http://www.intogen.org/search?gene=PAX5)
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IV-11 CIViC 
(https://civic.genome.wustl.edu/#/home) 
The CIViC (Clinical Interpretations of Variants in 
Cancer) database is based on Evidence items which 
reference their parent variants, variant groups, and 
genes. One can explore the various CIViC entities 
and their attributes using the menu. Precision 
medicine refers to the use of prevention and treatment 
strategies that are tailored to the unique features of 
each individual and their disease. In the context of 
cancer, this might involve the identification of 
specific mutations shown to predict response to a 
targeted therapy. The biomedical literature describing 
these associations is large and growing rapidly. 
Currently these interpretations exist largely in private 
or encumbered databases resulting in extensive 
repetition of effort. Currently this database is just 
starting with 212 genes (474 variants) analysed from 
870 publications.  
IV-12 ExAC 
(http://exac.broadinstitute.org)  
ExAC (Exome Aggregation Consortium) is a 
coalition of investigators seeking to aggregate and 
harmonize exome sequencing data from a variety of 
large-scale sequencing projects, and to make 
summary of the data available for the wider scientific 
community. The data set provided on this website 
spans across 60,706 unrelated individuals sequenced 
as part of various disease-specific and population 
genetic studies. All of the raw data from these 
projects have been reprocessed through the same 
pipeline, and jointly variant-called to increase 
consistency across projects. The data are available 
under the ODC Open Database License (ODbL). One 
is allowed to freely share and modify the ExAC data 
as long as it is of public use of the database, or work 
produced from the database, with keeping the 
resulting data-sets open and offering the shared or 
adapted version of the data under the same ODbL 
license (Minikel EV et al., 2016). 
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